文献速递白血病造血干细胞移植与细胞治疗

1期儿童CAR-T细胞试验前30天不良事件的综合分析

A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials.
PubMed 文献 · Blood Adv · 2023-01-01

这项回顾性单中心研究分析了134例参加3项1期CAR-T细胞试验(靶向CD19和/或CD22)的儿童和年轻成人患者,在输注后前30天按不良事件通用术语标准分级的不良事件。133例(99.3%)发生至少1项≥3级不良事件,涉及17个器官系统,其中75项(4.4%)被认为是剂量限制性或治疗限制性毒性。

要点

  • 133例(99.3%)患者发生至少1项≥3级不良事件,涉及17个器官系统。
  • 75项(4.4%)不良事件被认为是剂量限制性或治疗限制性毒性。
  • 排除血细胞减少后,109例(81.3%)发生≥3级非血细胞减少不良事件,中位3项。

核心结论

  • 儿童和年轻成人CAR-T细胞治疗后前30天器官特异性不良事件常见,≥3级非血细胞减少不良事件的发生与细胞因子释放综合征的发生及严重程度以及输注前疾病负荷(骨髓原始细胞≥25%)相关。
  • 随着CAR-T细胞疗法种类扩大,更深入理解这些毒性并预测哪些患者可能经历更多毒性至关重要。

研究设计与样本

  • 回顾性、单中心研究,分析134例参加3项1期CAR-T细胞试验(NCT01593696、NCT02315612、NCT03448393)的儿童和年轻成人患者,靶向CD19和/或CD22,评估输注后前30天的不良事件(按不良事件通用术语标准分级)。
  • 本研究为回顾性研究,注册号为NCT03827343。

主要发现

  • 133例(99.3%)患者发生至少1项≥3级不良事件,涉及17个器官系统,其中75项(4.4%)被认为是剂量限制性或治疗限制性毒性。
  • 排除血细胞减少后,109例(81.3%)发生≥3级非血细胞减少不良事件,中位3项。
  • ≥3级非血细胞减少不良事件的发生率与细胞因子释放综合征的发生及严重程度以及输注前疾病负荷(骨髓原始细胞≥25%)相关。
  • 达到完全缓解者较无应答者经历更多≥3级非血细胞减少不良事件的趋势(中位4 vs 3)。
  • 发生细胞因子释放综合征的无应答者(n=17;37.8%)在所有患者中非血细胞减少不良事件程度最高(中位7 vs 发生细胞因子释放综合征的应答者4)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The tremendous success of chimeric antigen receptor (CAR) T cells in children and young adults (CAYAs) with relapsed/refractory B-cell acute lymphoblastic leukemia is tempered by toxicities such as cytokine release syndrome (CRS). Despite expansive information about CRS, profiling of specific end-organ toxicities secondary to CAR T-cell therapy in CAYAs is limited. This retrospective, single-center study sought to characterize end-organ specific adverse events (AEs) experienced by CAYAs during the first 30 days after CAR T-cell infusion. AEs graded using Common Terminology Criteria for Adverse Events were retrospectively analyzed for 134 patients enrolled in 1 of 3 phase 1 CAR T-cell trials (NCT01593696, NCT02315612, and NCT03448393), targeting CD19 and/or CD22. A total of 133 patients (99.3%) experienced at least 1 grade ≥3 (≥Gr3) AE across 17 organ systems, of which 75 (4.4%) were considered dose- or treatment-limiting toxicities. Excluding cytopenias, 109 patients (81.3%) experienced a median of 3 ≥Gr3 noncytopenia (NC) AEs. The incidence of ≥Gr3 NC AEs was associated with the development and severity of CRS as well as preinfusion disease burden (≥ 25% marrow blasts). Although those with complete remission trended toward experiencing more ≥Gr3 NC AEs than nonresponders (median, 4 vs 3), nonresponders experiencing CRS (n = 17; 37.8%) had the highest degree of NC AEs across all patients (median, 7 vs 4 in responders experiencing CRS). Greater understanding of these toxicities and the ability to predict which patients may experience more toxicities is critical as the array of CAR T-cell therapies expand. This retrospective study was registered at www.clinicaltrials.gov as NCT03827343.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Silbert SK, Madan S, Holland EM, et al. A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials. Blood Adv. 2023. PMID: 37486616. doi:10.1182/bloodadvances.2023009789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。